摘要
SomaScan技术通过化学修饰的DNA适配体实现超高灵敏度(飞摩尔级)与高通量(>11000种蛋白)检测,克服了传统方法(如酶联免疫吸附测定、质谱)在低丰度蛋白筛查中的局限。该技术在心血管疾病、肿瘤、代谢性疾病等领域生物标志物发现中展现出巨大应用价值,包括早期风险预测(如心力衰竭标志物生长分化因子15)、疾病分型(如糖尿病亚型)、治疗响应评估(如免疫治疗预测模型PROphet)等。此外,针对SomaScan技术的临床转化,当前研究致力于解决技术标准化、多组学数据整合及微型化设备开发等关键路径。SomaScan技术为精准医疗提供了强有力的蛋白质组学工具。
SomaScan utilizes chemically modified DNA aptamers to achieve ultra-sensitive(fmol level)and high-throughput(>11000 proteins)quantification,overcoming the low-abundance protein limitation inherent in traditional methods such as enzyme-linked immunosorbent assay and mass-spectrometry.The technology has shown its great applicative value in biomarker discovery across cardiovascular disease,oncology and metabolic disorders,including early risk prediction(e.g.,heart-failure marker growth differentiation factor-15),disease subtyping(e.g.,diabetes subtypes)and therapy-response assessment(e.g.,the PROphet immunotherapy-prediction model).In addition,regarding the clinical translation of SomaScan technology,current research is dedicated to addressing key pathways such as technical standardization,multi-omics data integration,and minia-turized device development.SomaScan technology offers a powerful proteomic tool for precision medicine.
作者
石洋娜
龚文玉
SHI Yangna;GONG Wenyu(Department of Internal Medicine,the First Affiliated Hospital of Jinan University,Guangzhou 510632,China;Department of Nephrology,the First Affiliated Hospital of Jinan University,Guangzhou 510632,China)
出处
《医学综述》
2025年第21期2579-2585,共7页
Medical Recapitulate
基金
广东省本科高校“新医科”教学改革项目(2023140)
暨南大学教学调研项目(202413)
广东省研究生教育创新计划项目(2025SQXX_004)。
